HealthLynked (HLYK) AI Stock Analysis

• Market Cap: $6.99M
• Dividend Yield: N/A
• Average Volume (3M): 55.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: -44.11%
• EPS Growth: -45.07%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Care Facilities
• EPS (TTM): -0.02
• Shares Outstanding: 281,947,140
• 10 Day Avg. Volume: 35,980
• 30 Day Avg. Volume: 55,162
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.87
• Enterprise Value/Revenue: 4.71
• Enterprise Value/Gross Profit: 6.00
• Enterprise Value/Ebitda: -3.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and negative equity. Technical analysis indicates a bearish trend, with the stock trading below key moving averages. Valuation metrics are unfavorable due to negative earnings and lack of dividend yield.

HealthLynked Business Overview & Revenue Model

Company Description

HealthLynked (HLYK) is a healthcare technology company that operates within the healthcare sector, focusing on providing a comprehensive platform for patients and healthcare providers. The company offers services that include a blockchain-based health record management system, telehealth services, and patient engagement solutions. HealthLynked aims to improve healthcare accessibility and streamline the management of health data, fostering better communication between patients and providers.

How the Company Makes Money

HealthLynked generates revenue through multiple streams, primarily derived from subscription fees for its health record management services and telehealth platform. The company charges healthcare providers for access to its software solutions, which facilitate patient data management and telemedicine consultations. Additionally, HealthLynked may earn revenue from partnerships with healthcare institutions that utilize its platform to enhance their service offerings. The company also explores opportunities in data analytics and health information exchange, potentially monetizing aggregated health data while ensuring patient privacy. Overall, its diverse revenue model is supported by an increasing demand for digital health solutions and the ongoing transition toward value-based care in the healthcare industry.

HealthLynked Financial Statement Overview

Summary

HealthLynked is experiencing severe financial difficulties, characterized by declining revenues, substantial net losses, and negative stockholders' equity. The company has a negative debt-to-equity ratio and relies on external financing due to consistently negative cash flows.

Income Statement

The income statement shows declining revenues from $9,197,992 in 2021 to $3,008,361 in 2024, indicating significant revenue contraction. Gross profit margins remained relatively high, but the company experienced substantial net losses, increasing from -$1,012,203 in 2023 to -$6,131,479 in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges and negative earnings before interest and taxes.

Balance Sheet

The balance sheet reveals a negative stockholders' equity of -$3,129,209 in 2024, down from $804,730 in 2023, highlighting financial instability. The debt-to-equity ratio is effectively unmeasurable due to negative equity, suggesting high leverage. The equity ratio is negative, indicating liabilities exceed assets, signaling potential insolvency risks.

Cash Flow

Cash flow analysis shows consistently negative free cash flow, with -$3,494,122 in 2024. Operating cash flow is negative, indicating the company is not generating sufficient cash from operations to cover its expenses. There is a slight improvement in financing cash flow, suggesting reliance on external financing to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.01M	5.72M	5.86M	9.20M	6.13M
Gross Profit	2.91M	2.35M	5.40M	6.18M	4.97M
EBITDA	-4.36M	-2.75M	-7.05M	-9.85M	-4.73M
Net Income	-6.13M	-1.01M	-8.82M	-10.41M	-6.15M
Balance Sheet
Total Assets	2.22M	4.28M	4.58M	10.69M	8.03M
Cash, Cash Equivalents and Short-Term Investments	76.24K	247.22K	61.89K	3.29M	162.18K
Total Debt	997.85K	1.97M	1.28M	978.19K	2.89M
Total Liabilities	5.35M	3.48M	4.27M	3.49M	6.68M
Stockholders Equity	-3.13M	804.73K	314.45K	7.20M	1.35M
Cash Flow
Free Cash Flow	-3.50M	-4.15M	-4.39M	-3.79M	-2.14M
Operating Cash Flow	-3.49M	-4.14M	-4.36M	-3.77M	-2.12M
Investing Cash Flow	422.40K	3.51M	-544.75K	-341.36K	1.81M
Financing Cash Flow	2.90M	824.09K	1.68M	7.24M	356.80K

HealthLynked Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HLYK.

HealthLynked Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	70 Outperform	$16.00M	11.26	6.16%	―	35.25%	175.21%
Sector *	51 Neutral	$7.35B	-0.20	-44.86%	2.33%	28.96%	-1.05%
CCEL	49 Neutral	$39.88M	380.00	93.38%	8.16%	1.10%	98.13%
PIII	49 Neutral	$47.44M	―	-131.17%	―	9.79%	-47.01%
MODV	48 Neutral	$32.58M	―	-951.52%	―	-0.70%	-2.38%
HLYK	41 Neutral	$6.99M	―	320.09%	―	-44.11%	-45.07%
CCM	40 Underperform	$21.27M	―	14.03%	―	-29.82%	-2.57%

HealthLynked Corporate Events

HealthLynked Appoints New CFO Amid Leadership Changes

HealthLynked Corp. announced the appointment of Jeremy Daniel as its new Chief Financial Officer, effective January 15, 2025, following the resignation of David Rosal. Jeremy Daniel, with over two decades of experience in financial management and strategic planning across diverse industries, is expected to strengthen HealthLynked’s executive leadership and drive the company’s financial strategy, growth, and operational efficiency.